The PRMRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals. The proposed experiments may be hypothesis or milestone driven. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families. The product(s) to be developed under the FY25 PRMRP TTDA mechanism may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A “knowledge product” is a non-materiel product that addresses an identified need in a topic area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
Deadlines:
• Required Pre-Application Deadline: June 9, 2025
• Application Submission Deadline: July 21, 2025
- AUTOIMMUNE DISORDERS AND IMMUNOLOGY
- CARDIOVASCULAR HEALTH
- INFECTIOUS DISEASES
- INTERNAL MEDICINE
- NEUROSCIENCE AND BEHAVIORAL HEALTH
- ORTHOPAEDIC MEDICINE
- RARE DISEASES AND CONDITIONS
- RESPIRATORY HEALTH
Investigators at or above the level of Assistant Professor (or equivalent) may be named by the organization as the Principal Investigator (PI) on the application.
Industry titles may not be analogous to the faculty hierarchy in academia. For industry, investigators at or above an independent scientist level may be named by the company as the PI on the application.
Each investigator may be named on only one FY25 PRMRP application as a PI, which includes the FY25 PRMRP TTDA and the FY25 PRMRP Clinical Trial Award (HT942525PRMRPCTA). If more than one Letter of Intent (LOI) is submitted by the PI to the FY25 PRMRP, the first submission will be accepted, and the second will be administratively withdrawn.
Individuals affiliated with an eligible organization are eligible to be named as PI regardless of ethnicity, nationality, or citizenship status.
The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $41.25 million (M) to fund approximately 11 Technology/Therapeutic Development Award applications with direct cost caps of $2.5M. The maximum period of performance is 4 years. It is anticipated that awards made from this fiscal year 2025 (FY25) funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026.